foxo4-dri user experiences anecdotal reports Results: What to Expect (2026) FOXO4-DRI - Wikipedia
Description
By activating GLP-1 receptors, semaglutide suppresses appetite, reduces hunger cravings, and lowers calorie intake
Preclinical research evidence Animal Experiments Obese mouse model: After subcutaneous injection of AOD 9604 (250 g/kg) daily for 8 weeks, the body weight of obese mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue decreased significantly
AOD-9604 is not a nervous system stimulant (like caffeine or other thermogenics)
One of them is a lack of exercise
